High-dose radiotherapy with helical tomotherapy and long-term androgen deprivation therapy for prostate cancer: 5-year outcomes
Tomita N, Soga N, Ogura Y, Hayashi N, Kageyama T, Ito M, Koide Y, Yoshida M, Kimura K, Makita C, Tachibana H, Kodaira T | J Cancer Res Clin Oncol | 2016
Moderate Hypofractionation with Simultaneous Integrated Boost in Prostate Cancer: Long-term Results of a Phase I-II Study
Di Muzio NG, Fodor A, Noris Chiorda B, Broggi S, Mangili P, Valdagni R, Dell’Oca I, Pasetti M, Deantoni CL, Chiara A, Berardi G, Briganti A, Calandrino R, Cozzarini C, Fiorino C | Clin Oncol | 2016
High-Dose-Rate Brachytherapy Monotherapy versus Image-Guided Intensity-Modulated Radiotherapy with Helical Tomotherapy for Patients with Localized Prostate Cancer
Yamazaki H, Masui K, Suzuki G, Nakamura S, Shimizu D, Nishikawa T, Okabe H, Yoshida K, Kotsuma T, Tanaka E, Otani K, Yoshioka Y, Ogawa K | Cancers (Basel) | 2018
Intensity-Modulated Radiation Therapy with Simultaneous Integrated Boost for Clinically Node-Positive Prostate Cancer: A Single-Institutional Retrospective Study
Onishi M, Kawamura H, Murata K, Inoue T, Murata H, Takakusagi Y, Okonogi N, Ohkubo Y, Okamoto M, Kaminuma T, Sekihara T, Nakano T, Ohno T | Cancers (Basel) | 2021
Post-operative hypofractionated radiotherapy for prostate cancer: a mono-institutional analysis of toxicity and clinical outcomes
Ferrera G, D’Alessandro S, Cuccia F, Serretta V, Trapani G, Savoca G, Mortellaro G, Lo Casto A | J Cancer Res Clin Oncol | 2022
Moderate Hypofractionated Helical TomoTherapy for Older Patients with Localized Prostate Cancer: Long-term Outcomes of a Phase I-II Trial
Cui D, Du L, Yu W, Cai B, Meng L, Yang J, Luo Y, Chen J, and Ma L | Radiol Oncol| 2022
Ultra-hypofractionated radiation therapy for unfavourable intermediate-risk and high-risk prostate cancer is safe and effective: 5-year outcomes of a phase II trial
Macias VA, Barrera-Mellado I | BJU Int | 2020
Multicenter Trial of Stereotactic Body Radiation Therapy for Low- and Intermediate-Risk Prostate Cancer: Survival and Toxicity Endpoints
Meier RM, Bloch DA, Cotrutz C, Beckman AC, Henning GT, Woodhouse SA, Williamson SK, Mohideen N, Dombrowski JJ, Hong RL, Brachman DG, Linson PW, Kaplan ID. | Int J Radiat Oncol Biol Phys | 2018
Patient and Dosimetric Predictors of Genitourinary and Bowel Quality of Life After Prostate SBRT: Secondary Analysis of a Multi-institutional Trial
Wang K, Chen RC, Kane B, Medbery CA, Underhill K, Gray JR, Peddada AV, Fuller DB | Int J Radiat Oncol Biol Phys | 2018
5-year Biochemical Outcomes of Stereotactic Body Radiotherapy with Intraprostatic Dose Escalation for Unfavorable Prostate Cancer
Blacksburg SR, Aghdam N, Royce TJ, Burri RJ, Obayomi-Davies O, Mezeckis M, Meier R, Fuller DB, Chen RC, Lanciano RM, Haas JA, Collins SP | Int J Radiat Oncol Biol Phys | 2019
Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial
Brand DH, Tree AC, Ostler P, van der Voet H, Loblaw A, Chu W, Ford D, Tolan S, Jain S, Martin A, Staffurth J, Camilleri P, Kancherla K, Frew J, Chan A, Dayes IS, Henderson D, Brown S, Cruickshank C, Burnett S, Duffton A, Griffin C, Hinder V, Morrison K, Naismith O, Hall E, van […]
Prostate SBRT: Comparison the Efficacy and Toxicity of Two Different Dose Fractionation Schedules
Fuller DB, Naitoh J, Shirazi R, Crabtree T, Mardirossian G | Front Oncol | 2020
Favorable Biochemical Freedom From Recurrence With Stereotactic Body Radiation Therapy for Intermediate and High-Risk Prostate Cancer: A Single Institutional Experience With Long-Term Follow-Up
Ricco A, Barbera G, Lanciano R, Feng J, Hanlon A, Lozano A, Good M, Arrigo S, Lamond J, Yang J | Front Oncol | 2020
Acute side effects after definitive stereotactic body radiation therapy (SBRT) for patients with clinically localized or locally advanced prostate cancer: a single institution prospective study
Jorgo K, Polgar C, Stelczer G, Major T, Gesztesi L, Agoston P | Radiol Oncol | 2021
Bleeding Risk Following Stereotactic Body Radiation Therapy for Localized Prostate Cancer in Men on Baseline Anticoagulant or Antiplatelet Therapy
Pepin A, Shah S, Pernia M, Lei S, Ayoob M, Danner M, Yung T, Collins BT, Suy S, Aghdam N, Collins SP | Front Oncol | 2021
Five-year outcomes of stereotactic body radiation therapy (SBRT) for prostate cancer: the largest experience in China
Zhao X, Ye Y, Yu H, Jiang L, Cheng C, Guo X, Ju X, Zhu X, Zhang H. | J Cancer Res Clin Oncol | 2021
Bothersome Hematospermia Following Stereotactic Body Radiation Therapy for Prostate Cancer
Sarthak Shah, Tamir Sholklapper , Michael Creswell, Abigail Pepin , Jonathan Cantalino, Ryan Andrew Hankins, Simeng Suy, Sean P Collins | Front Oncol | 2021
Short-Term Outcomes and Clinical Efficacy of Stereotactic Body Radiation Therapy (SBRT) for Oligometastases of Prostate Cancer in China
Chenyang Xu, Xianzhi Zhao, Xiaoping Ju, Yuxin Shen, Min Qu, Yusheng Ye, Xiaoyan Wang, Chunshan Yu, Xu Gao, Huojun Zhang | Front Oncol | 2022
High Dose “HDR-Like” Prostate SBRT: PSA 10-Year Results From a Mature, Multi-Institutional Clinical Trial
Fuller DB, Crabtree T, Kane BL, Medbery CA, Pfeffer R, Gray JR, Peddada A, Royce TJ, Chen RC | Front Oncol | 2022
